Cancer Immunotherapy Program News

Every person on your child’s team has the same goal: to give your child the best possible care. We provide medical care, emotional support and much more. Each team member has extensive experience in the treatment of children using immunotherapy.

How we serve you

Existing patients or family members

215-590-3025

New patients, referrals and second opinions

267-426-0762

CHOP Treats 500th CAR T Patient

Jul 17, 2023

CHOP has treated its 500th patient with CAR T-cell immunotherapy, a “living drug” that harnesses the power of a patient’s own immune system to fight cancer.

Two CHOP Researchers Named 2022 STAT Wunderkinds

Dec 1, 2022

Two researchers from Children’s Hospital of Philadelphia (CHOP) were recently selected by the health and science news outlet STAT as 2022 Wunderkinds, an award that celebrates the next generation of scientific superstars who are making significant contributions to biomedical research.

New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response

Nov 28, 2022

A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.

CHOP Study Finds CAR T-Cell Therapy Improves Survival Regardless of Socioeconomic Status

Nov 10, 2022

Researchers from Children’s Hospital of Philadelphia (CHOP) have found that economically disadvantaged children treated with CAR T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (ALL) fair just as well as children from more socioeconomically advantaged backgrounds.

CHOP Study Offers Proof of Concept for Treating Pediatric Brain Tumors with Immunotherapy

Nov 1, 2022

CHOP researchers have identified a protein on the surface of multiple pediatric brain tumors that they can target using immunotherapy in preclinical models.

First Approved CAR T-Cell Therapy Shows Continued Benefits Five Years Later

Jun 16, 2022

New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.

New Data Show Benefits of CRISPR-edited Gene Therapy for Blood Disorders in a Larger Patient Group with Longer-Term Follow-Up

Jun 14, 2022

A group of researchers that includes CHOP presented new data on CRISPR-edited gene therapy for blood disorders at an international meeting.

Find a research study

Innovation and your child

Find research studies